GlassScriptPhysician profile
Emily D Freeman
NPI 1285076018
$4,906.72
in general payments reported to CMS, 2019-2025
32 companies · $778 in 2025
The $778 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $542 · 2022: $1,098 · 2023: $1,403 · 2024: $1,087 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,020 · Education: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,020.22 |
| Education | $247.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $833.41 | 2021-2025 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $790.00 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $387.40 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Harmony Biosciences LLC | $304.68 | 2022-2025 | Wakix |
| Insmed, INC. | $266.47 | 2023-2025 | Arikayce |
| Gilead Sciences, INC. | $263.88 | 2021-2024 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.38 | 2021-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $247.39 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $185.38 | 2022-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $165.85 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Axsome Therapeutics, INC. | $147.08 | 2024 | Sunosi |
| Mallinckrodt Hospital Products INC. | $123.69 | 2023 | Acthar |
| United Therapeutics Corporation | $121.15 | 2022-2024 | Tyvaso |
| Philips North America LLC | $118.00 | 2021-2024 | (Ak6) Vest Therapy |
| Mylan Specialty L.P. | $104.32 | 2021-2024 | Yupelri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $93.33 | 2024 | Inspire |
| Amgen INC. | $83.61 | 2023-2025 | Tezspire |
| Genzyme Corporation | $62.27 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $40.51 | 2021-2023 | Cinqair |
| Electromed, INC. | $34.12 | 2023-2024 | Smartvest |
| Viatris Specialty LLC | $33.74 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $33.06 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $30.79 | 2022-2023 | Dificid, Zerbaxa, Recarbrio |
| Abiomed | $24.92 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $22.48 | 2021 | |
| Verona Pharma, INC. | $22.22 | 2025 | Ohtuvayre |
| Csl Behring | $21.51 | 2022 | |
| Genentech USA, INC. | $18.70 | 2023 | Xolair |
| Bayer Healthcare Pharmaceuticals INC. | $18.08 | 2025 | |
| Chiesi USA, INC. | $15.62 | 2022 | |
| Bard Peripheral Vascular, INC. | $15.53 | 2023 | |
| Resmed Corp | $14.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.